Overview

A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma

Status:
Not yet recruiting
Trial end date:
2027-12-15
Target enrollment:
Participant gender:
Summary
This study is aimed to evaluate the efficacy and safety of sintilimab combined with chemotherapy versus chemotherapy in perioperative treatment of locally advanced esophageal squamous cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Collaborator:
Innovent Biologics (Suzhou) Co. Ltd.